{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T14:40:13Z","timestamp":1787582413945,"version":"build-2736575974"},"reference-count":258,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Problems in Pediatric and Adolescent Health Care"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.cppeds.2024.101637","type":"journal-article","created":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T11:35:53Z","timestamp":1716896153000},"page":"101637","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Update on advances in cystic fibrosis towards a cure and implications for primary care clinicians"],"prefix":"10.1016","volume":"54","author":[{"given":"Vito","family":"Terlizzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip M.","family":"Farrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cppeds.2024.101637_bib0001","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1001\/archpedi.1938.01980140114013","article-title":"Cystic fibrosis of the pancreas and its relation to celiac disease","volume":"56","author":"Andersen","year":"1938","journal-title":"Am J Dis Child"},{"key":"10.1016\/j.cppeds.2024.101637_bib0002","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1542\/peds.12.5.549","article-title":"Abnormal electrolyte composition of sweat in cystic fibrosis of the pancreas; clinical significance and relationship to the disease","volume":"12","author":"di Sant'Agnese","year":"1953","journal-title":"Pediatrics"},{"key":"10.1016\/j.cppeds.2024.101637_bib0003","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1056\/NEJM198305193082002","article-title":"Higher bioelectric potentials due to decreased chloride absorption in the sweat glands of patients with cystic fibrosis","volume":"308","author":"Quinton","year":"1983","journal-title":"N Engl J Med"},{"issue":"2 Pt 1","key":"10.1016\/j.cppeds.2024.101637_bib0004","first-page":"L47","article-title":"The search for the cystic fibrosis gene","volume":"257","author":"Buchwald","year":"1989","journal-title":"Am J Physiol"},{"key":"10.1016\/j.cppeds.2024.101637_bib0005","first-page":"1066","article-title":"Identification of the cystic fibrosis gene: cloning and characterization of complementary","volume":"245","author":"Riordan","year":"1989","journal-title":"DNA Science"},{"key":"10.1016\/j.cppeds.2024.101637_bib0006","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1126\/science.2570460","article-title":"Identification of the cystic fibrosis gene: genetic analysis","volume":"245","author":"Kerem","year":"1989","journal-title":"Science"},{"issue":"1 Suppl","key":"10.1016\/j.cppeds.2024.101637_bib0007","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1152\/physrev.1999.79.1.S23","article-title":"Structure and function of the CFTR chloride channel","volume":"79","author":"Sheppard","year":"1999","journal-title":"Physiol Rev"},{"issue":"6","key":"10.1016\/j.cppeds.2024.101637_bib0008","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/humu.10041","article-title":"Cystic fibrosis: a worldwide analysis of CFTR mutations\u2013correlation with incidence data and application to screening","volume":"19","author":"Bobadilla","year":"2002","journal-title":"Hum Mutat"},{"issue":"4","key":"10.1016\/j.cppeds.2024.101637_bib0009","first-page":"524","article-title":"Sweat chloride concentrations in infants homozygous or heterozygous for F508 cystic fibrosis","volume":"97","author":"Farrell","year":"1996","journal-title":"Pediatrics"},{"key":"10.1016\/j.cppeds.2024.101637_bib0010","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","article-title":"The future of cystic fibrosis care: a global perspective","volume":"8","author":"Bell","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"12","key":"10.1016\/j.cppeds.2024.101637_bib0011","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1038\/s41431-018-0234-z","article-title":"Estimating the age of p.(Phe508del) with family studies of geographically distinct European populations and the early spread of cystic fibrosis","volume":"26","author":"Farrell","year":"2018","journal-title":"Eur J Hum Genet"},{"issue":"12","key":"10.1016\/j.cppeds.2024.101637_bib0012","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1002\/ppul.25658","article-title":"Outcomes of infants born during the first 9 years of CF newborn screening in the United States: a retrospective Cystic Fibrosis Foundation Patient Registry cohort study","volume":"56","author":"Martiniano","year":"2021","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.cppeds.2024.101637_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2023.113595","article-title":"Late diagnosis in the era of universal newborn screening negatively affects short- and long-term growth and health outcomes in infants with cystic fibrosis","volume":"262","author":"Martiniano","year":"2023","journal-title":"J Pediatr"},{"issue":"2","key":"10.1016\/j.cppeds.2024.101637_bib0014","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ccm.2007.02.006","article-title":"Nutrition and lung disease in cystic fibrosis","volume":"28","author":"Milla","year":"2007","journal-title":"Clin Chest Med"},{"key":"10.1016\/j.cppeds.2024.101637_bib0015","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1146\/annurev.genom.6.080604.162254","article-title":"Modifier genetics: cystic fibrosis","volume":"6","author":"Cutting","year":"2005","journal-title":"Annu Rev Genom Hum Genet"},{"key":"10.1016\/j.cppeds.2024.101637_bib0016","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1146\/annurev-genom-083117-021329","article-title":"Cystic fibrosis disease modifiers: complex genetics defines the phenotypic diversity in a monogenic disease","volume":"19","author":"O'Neal","year":"2018","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"10.1016\/j.cppeds.2024.101637_bib0017","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1080\/17476348.2016.1196140","article-title":"Socioeconomic status and health outcomes: cystic fibrosis as a model","volume":"10","author":"Oates","year":"2016","journal-title":"Expert Rev Respir Med"},{"issue":"11","key":"10.1016\/j.cppeds.2024.101637_bib0018","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1002\/ppul.26625","article-title":"Impact of intrinsic and extrinsic risk factors on early-onset lung disease in cystic fibrosis","volume":"58","author":"Huang","year":"2023","journal-title":"Pediatr Pulmonol"},{"issue":"6","key":"10.1016\/j.cppeds.2024.101637_bib0019","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1001\/jamapediatrics.2017.0206","article-title":"Baby observational and nutrition study (bonus) investigators of the cystic fibrosis foundation therapeutics development network. Effects of diagnosis by newborn screening for cystic fibrosis on weight and length in the first year of life","volume":"171","author":"Leung","year":"2017","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.cppeds.2024.101637_bib0020","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1093\/ajcn\/54.3.578","article-title":"Nutritional status of infants with cystic fibrosis associated with early diagnosis and intervention","volume":"54","author":"Marcus","year":"1991","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.cppeds.2024.101637_bib0021","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1056\/NEJMoa1301725","article-title":"Risk factors for bronchiectasis in children with cystic fibrosis","volume":"368","author":"Sly","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cppeds.2024.101637_bib0022","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/ppul.25825","article-title":"Vitamins A, D, E status as related to supplementation and lung disease markers in young children with cystic fibrosis","volume":"57","author":"Lai","year":"2022","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.cppeds.2024.101637_bib0023","series-title":"Newborn Screening for Cystic Fibrosis: Evaluation of Benefits and Risks and Recommendations for State Newborn Screening Programs","first-page":"1","author":"Grosse","year":"2004"},{"issue":"1","key":"10.1016\/j.cppeds.2024.101637_bib0024","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/ppul.26734","article-title":"Severe lung disease in children with cystic fibrosis missed in newborn screening","volume":"59","author":"Baldwin","year":"2024","journal-title":"Pediatr Pulmonol"},{"issue":"10","key":"10.1016\/j.cppeds.2024.101637_bib0025","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1001\/jamapediatrics.2022.2674","article-title":"Real-world associations of US cystic fibrosis newborn screening programs with nutritional and pulmonary outcomes","volume":"176","author":"Rosenfeld","year":"2022","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.cppeds.2024.101637_bib0026","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3390\/ijns6010018","article-title":"Newborn screening for CF across the globe- where is it worthwhile?","volume":"6","author":"Scotet","year":"2020","journal-title":"Int J Neonatal Screen"},{"key":"10.1016\/j.cppeds.2024.101637_bib0027","first-page":"445","article-title":"Newborn screening for cystic fibrosis. The methods compared on 229,626 newborns tested in 8 years in the Veneto Region","volume":"9","author":"Pederzini","year":"1983","journal-title":"It J Pediatr"},{"key":"10.1016\/j.cppeds.2024.101637_bib0028","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/S0022-3476(95)70040-4","article-title":"Neonatal screening for cystic fibrosis: a comparison of two strategies for case detection in 1.2 million babies","volume":"127","author":"Wilcken","year":"1995","journal-title":"J Pediatr"},{"issue":"4","key":"10.1016\/j.cppeds.2024.101637_bib0029","first-page":"295","article-title":"D\u00e9pistage n\u00e9onatal syst\u00e9matique de la mucoviscidose par dosage de la trypsine immunor\u00e9active sanguine. Bilan de 80 000 tests [Systematic neonatal screening for mucoviscidosis using an immunoreactive trypsin blood assay. Evaluation of 80,000 tests]","volume":"40","author":"Travert","year":"1983","journal-title":"Arch Fr Pediatr"},{"issue":"12","key":"10.1016\/j.cppeds.2024.101637_bib0030","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1136\/archdischild-2012-301968","article-title":"Thirty-years of screening for cystic fibrosis in East Anglia","volume":"97","author":"Calvin","year":"2012","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.cppeds.2024.101637_bib0031","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1056\/NEJM199109123251104","article-title":"Efficacy of state-wide neonatal screening for cystic fibrosis by assay of trypsinogen concentrations","volume":"325","author":"Hammond","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cppeds.2024.101637_bib0032","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S0140-6736(79)90825-0","article-title":"Dried-blood spot screening for cystic fibrosis in the newborn","volume":"1","author":"Crossley","year":"1979","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.cppeds.2024.101637_bib0033","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ymgme.2012.02.013","article-title":"Immunoreactive Trypsinogen (IRT) as a Biomarker for cystic fibrosis: challenges in newborn dried blood spot screening","volume":"106","author":"Therrell","year":"2012","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.cppeds.2024.101637_bib0034","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/ppul.26279","article-title":"Variation in cystic fibrosis newborn screening algorithms in the United States","volume":"58","author":"Rehani","year":"2023","journal-title":"Pediatr Pulmonol"},{"issue":"4","key":"10.1016\/j.cppeds.2024.101637_bib0035","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3390\/genes11040401","article-title":"The impact of the cftr gene discovery on cystic fibrosis diagnosis, counseling, and preventive therapy","volume":"11","author":"Farrell","year":"2020","journal-title":"Genes"},{"issue":"11","key":"10.1016\/j.cppeds.2024.101637_bib0036","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1002\/ppul.26621","article-title":"Cystic fibrosis screen-positive neonates with one pathogenic variant still warrant sweat testing","volume":"58","author":"Rock","year":"2023","journal-title":"Pediatr Pulmonol"},{"issue":"1\u20132","key":"10.1016\/j.cppeds.2024.101637_bib0037","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ymgme.2021.08.008","article-title":"Challenging the dogma of the healthy heterozygote: implications for newborn screening policies and practices","volume":"134","author":"Farrell","year":"2021","journal-title":"Mol Genet Metab"},{"issue":"3","key":"10.1016\/j.cppeds.2024.101637_bib0038","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/ppul.26253","article-title":"Refinement of newborn screening for cystic fibrosis with next generation sequencing","volume":"58","author":"Rock","year":"2023","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.cppeds.2024.101637_bib0039","first-page":"1170","article-title":"Early childhood risk factors for decreased FEV1 at age six to seven years in young children with cystic fibrosis","volume":"12","author":"Sanders","year":"2015","journal-title":"Ann Am Thorac Soc"},{"issue":"1","key":"10.1016\/j.cppeds.2024.101637_bib0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1542\/peds.107.1.1","article-title":"Early diagnosis of cystic fibrosis through neonatal screening prevents severe malnutrition and improves long-term growth. Wisconsin Cystic Fibrosis Neonatal Screening Study Group","volume":"107","author":"Farrell","year":"2001","journal-title":"Pediatrics"},{"key":"10.1016\/j.cppeds.2024.101637_bib0041","doi-asserted-by":"crossref","first-page":"S106","DOI":"10.1016\/j.jpeds.2009.09.003","article-title":"Cystic Fibrosis Foundation practice guidelines for the management of infants with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome during the first two years of life and beyond","volume":"155","author":"Borowitz","year":"2009","journal-title":"J Pediatr"},{"key":"10.1016\/j.cppeds.2024.101637_bib0042","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.jcf.2015.01.001","article-title":"ECFS Neonatal Screening Working Group. Cystic Fibrosis Screen Positive, Inconclusive Diagnosis (CFSPID): a new designation and management recommendations for infants with an inconclusive diagnosis following newborn screening","volume":"14","author":"Munck","year":"2015","journal-title":"J Cyst Fibros"},{"issue":"5","key":"10.1016\/j.cppeds.2024.101637_bib0043","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jcf.2020.11.006","volume":"20","author":"Castellani","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.cppeds.2024.101637_bib0044","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2016.09.066","article-title":"Cystic fibrosis transmembrane conductance regulator-related metabolic syndrome and cystic fibrosis screen positive, inconclusive diagnosis","author":"Ren","year":"2017","journal-title":"J Pediatr"},{"issue":"Suppl 2","key":"10.1016\/j.cppeds.2024.101637_bib0045","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1016\/S1569-1993(11)60014-3","article-title":"Recommendations for the classification of diseases as CFTR-related disorders","volume":"10","author":"Bombieri","year":"2011","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.cppeds.2024.101637_bib0046","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.jcf.2022.09.011","article-title":"ECFS standards of care on CFTR-related disorders: updated diagnostic criteria","volume":"21","author":"Castellani","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.cppeds.2024.101637_bib0047","doi-asserted-by":"crossref","first-page":"e1386","DOI":"10.1542\/peds.2014-3698","article-title":"Outcomes of infants with indeterminate diagnosis detected by cystic fibrosis newborn screening","volume":"135","author":"Ren","year":"2015","journal-title":"Pediatrics"},{"key":"10.1016\/j.cppeds.2024.101637_bib0048","doi-asserted-by":"crossref","first-page":"e1377","DOI":"10.1542\/peds.2014-2081","article-title":"Inconclusive diagnosis of cystic fibrosis after newborn screening","volume":"135","author":"Ooi","year":"2015","journal-title":"Pediatrics"},{"key":"10.1016\/j.cppeds.2024.101637_bib0049","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2021-051740","article-title":"Outcomes of cystic fibrosis screening-positive infants with inconclusive diagnosis at school age","volume":"148","author":"Gonska","year":"2021","journal-title":"Pediatrics"},{"key":"10.1016\/j.cppeds.2024.101637_bib0050","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1002\/ppul.24634","article-title":"Phenotype of children with inconclusive cystic fibrosis diagnosis after newborn screening","volume":"55","author":"Munck","year":"2020","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.cppeds.2024.101637_bib0051","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/ppul.25296","article-title":"Outcomes of repeat sweat testing in cystic fibrosis newborn screen positive infants","volume":"56","author":"Bauer","year":"2021","journal-title":"Pediatr Pulmonol"},{"issue":"5","key":"10.1016\/j.cppeds.2024.101637_bib0052","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2023-064657","article-title":"Cystic fibrosis foundation evidence-based guideline for the management of CRMS\/CFSPID","volume":"153","author":"Green","year":"2024","journal-title":"Pediatrics"},{"key":"10.1016\/j.cppeds.2024.101637_bib0053","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2023.1127659","article-title":"Outcomes of children with cystic fibrosis screen positive, inconclusive diagnosis\/CFTR related metabolic syndrome","volume":"11","author":"Gunnett","year":"2023","journal-title":"Front Pediatr"},{"issue":"5","key":"10.1016\/j.cppeds.2024.101637_bib0054","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.jcf.2021.03.015","article-title":"A survey of the prevalence, management and outcome of infants with an inconclusive diagnosis following newborn bloodspot screening for cystic fibrosis (CRMS\/CFSPID) in six Italian Centres","volume":"20","author":"Terlizzi","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.cppeds.2024.101637_bib0055","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3390\/ijns9030041","article-title":"Comparison between Gibson-Cooke and macroduct methods in the cystic fibrosis neonatal screening program and in subjects who are cystic fibrosis screen-positive with an inconclusive diagnosis","volume":"9","author":"Dolce","year":"2023","journal-title":"Int J Neonatal Screen"},{"key":"10.1016\/j.cppeds.2024.101637_bib0056","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3390\/children10020177","article-title":"A Multicentre Italian study on the psychological impact of an inconclusive cystic fibrosis diagnosis after positive neonatal screening","volume":"10","author":"Tosco","year":"2023","journal-title":"Children"},{"key":"10.1016\/j.cppeds.2024.101637_bib0057","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jcf.2022.12.002","article-title":"High rates of anxiety detected in mothers of children with inconclusive cystic fibrosis screening results","volume":"22","author":"Ginsburg","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.cppeds.2024.101637_bib0058","article-title":"Biochemical and genetic tools to predict the progression to cystic fibrosis in CRMS\/CFSPID subjects: a systematic review","author":"Terlizzi","year":"2024","journal-title":"Paediatr Respir Rev"},{"key":"10.1016\/j.cppeds.2024.101637_bib0059","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1186\/s12887-019-1756-4","article-title":"Immunoreactive trypsinogen levels in newborn screened infants with an inconclusive diagnosis of cystic fibrosis","volume":"19","author":"Ooi","year":"2019","journal-title":"BMC Pediatr"},{"key":"10.1016\/j.cppeds.2024.101637_bib0060","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1002\/ppul.24721","article-title":"Trend of sweat chloride values in a cohort of patients carrying CFTR mutations of varying clinical consequence: is there a risk of increasing sweat chloride over time?","volume":"55","author":"Terlizzi","year":"2020","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.cppeds.2024.101637_bib0061","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/ppul.26296","article-title":"Gradual increase in sweat chloride concentration is associated with a higher risk of CRMS\/CFSPID to CF reclassification","volume":"58","author":"Salinas","year":"2023","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.cppeds.2024.101637_bib0062","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.jcf.2023.04.018","article-title":"Variability of the sweat test in children with cystic fibrosis previously CRMS\/CFSPID: a retrospective monocenter experience","volume":"22","author":"Terlizzi","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.cppeds.2024.101637_bib0063","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jcf.2013.09.007","article-title":"Sweat chloride as a biomarker of CFTR activity: proof of concept and Ivacaftor clinical trial data","volume":"13","author":"Accurso","year":"2014","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.cppeds.2024.101637_bib0064","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cppeds.2024.101637_bib0065","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jcf.2016.02.015","article-title":"Variability of sweat chloride concentration in subjects with cystic fibrosis and G551D mutations","volume":"16","author":"Vermeulen","year":"2017","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.cppeds.2024.101637_bib0066","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.1002\/ppul.25683","article-title":"Outcomes of early repeat sweat testing in infants with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome\/CF screen-positive, inconclusive diagnosis","volume":"56","author":"Terlizzi","year":"2021","journal-title":"Pediatr Pulmonol"},{"issue":"5","key":"10.1016\/j.cppeds.2024.101637_bib0067","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0155624","article-title":"Benign and deleterious cystic fibrosis transmembrane conductance regulator mutations identified by sequencing in positive cystic fibrosis newborn screen children from California","volume":"11","author":"Salinas","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.cppeds.2024.101637_bib0068","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jcf.2022.07.007","article-title":"Different management approaches and outcome for infants with an inconclusive diagnosis following newborn screening for cystic fibrosis (CRMS\/CFSPID) and Pseudomonas aeruginosa isolation","volume":"22","author":"Dolce","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.cppeds.2024.101637_bib0069","doi-asserted-by":"crossref","first-page":"570","DOI":"10.3390\/diagnostics10080570","article-title":"Cystic fibrosis-screening positive inconclusive diagnosis: newborn screening and long-term follow-up permits to early identify patients with CFTR-related disorders","volume":"10","author":"Castaldo","year":"2020","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.cppeds.2024.101637_bib0070","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.jcf.2022.04.020","article-title":"Clinical outcomes of a large cohort of individuals with the F508del\/5T;TG12 CFTR genotype","volume":"21","author":"Tosco","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.cppeds.2024.101637_bib0071","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1513\/AnnalsATS.202201-024OC","article-title":"Cystic fibrosis screen positive, inconclusive diagnosis genotypes in people with cystic fibrosis from the U.S. Patient Registry","volume":"20","author":"Salinas","year":"2023","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.cppeds.2024.101637_bib0072","series-title":"Carrier Testing for Cystic Fibrosis","year":"2020"},{"key":"10.1016\/j.cppeds.2024.101637_bib0073","doi-asserted-by":"crossref","first-page":"965","DOI":"10.5694\/j.1326-5377.1962.tb27044.x","article-title":"Observations on (i) sweat sodium levels in relation to chronic respiratory disease in adults and (ii) the incidence of respiratory and other disease in parents and siblings of patients with fibrocystic disease of the pancreas","volume":"49","author":"Anderson","year":"1962","journal-title":"Med J Aust"},{"key":"10.1016\/j.cppeds.2024.101637_bib0074","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/S0140-6736(63)91926-3","article-title":"The prevalence of respiratory disease in heterozygotes for the gene for fibrocystic disease of the pancreas","volume":"281","author":"Batten","year":"1963","journal-title":"Lancet"},{"key":"10.1016\/j.cppeds.2024.101637_bib0075","first-page":"714","article-title":"Absence of detrimental effect of the carrier state for the cystic fibrosis gene","volume":"92","author":"Hallett","year":"1965","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.cppeds.2024.101637_bib0076","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1651-2227.1963.tb03779.x","article-title":"Anamnesis, sweat electrolyte and pulmonary function studies in parents of patients with cystic fibrosis of the pancreas","volume":"52","author":"Orzalesi","year":"1963","journal-title":"Acta P\u00e6diatr"},{"key":"10.1016\/j.cppeds.2024.101637_bib0077","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","article-title":"Cystic fibrosis","volume":"388","author":"Elborn","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.cppeds.2024.101637_bib0078","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/S0960-9822(00)00166-4","article-title":"Human genetics: what is good about cystic fibrosis?","volume":"4","author":"Quinton","year":"1994","journal-title":"Curr Biol"},{"key":"10.1016\/j.cppeds.2024.101637_bib0079","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s00439-005-0005-0","article-title":"Susceptibility to typhoid fever is associated with a poly- morphism in the cystic fibrosis transmembrane conductance regulator (CFTR)","volume":"118","author":"van de Vosse","year":"2005","journal-title":"Hum Genet"},{"key":"10.1016\/j.cppeds.2024.101637_bib0080","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/(SICI)1098-1004(1997)10:1<45::AID-HUMU6>3.0.CO;2-L","article-title":"The cystic fibrosis delta F508 gene mutation and cancer","volume":"10","author":"Padua","year":"1997","journal-title":"Hum Mutat"},{"issue":"3","key":"10.1016\/j.cppeds.2024.101637_bib0081","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/0306-9877(91)90144-N","article-title":"The cystic fibrosis heterozygote\u2013advantage in surviving cholera?","volume":"36","author":"Rodman","year":"1991","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.cppeds.2024.101637_bib0082","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/ajmg.a.30470","article-title":"Cystic fibrosis carriers have higher neonatal immunoreactive trypsinogen values than non-carriers","volume":"135A","author":"Castellani","year":"2005","journal-title":"Am J Med Genet"},{"key":"10.1016\/j.cppeds.2024.101637_bib0083","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1034\/j.1399-0004.2001.590107.x","article-title":"Prevalence of CFTR mutations in hypertrypsinaemia detected through neonatal screening for cystic fibrosis","volume":"59","author":"Scotet","year":"2001","journal-title":"Clin Genet"},{"key":"10.1016\/j.cppeds.2024.101637_bib0084","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1146\/annurev-med-042120-020148","article-title":"Clinical phenotypes of cystic fibrosis carriers","volume":"73","author":"Polgreen","year":"2022","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.cppeds.2024.101637_bib0085","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1089\/10906570152742317","article-title":"A pilot survey of cystic fibrosis clinical manifestations in CFTR mutation heterozygotes","volume":"5","author":"Castellani","year":"2001","journal-title":"Genet Test"},{"key":"10.1016\/j.cppeds.2024.101637_bib0086","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJM199506013322204","article-title":"Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens. N","volume":"332","author":"Chill\u00f3n","year":"1995","journal-title":"Engl J Med"},{"key":"10.1016\/j.cppeds.2024.101637_bib0087","doi-asserted-by":"crossref","first-page":"E13","DOI":"10.1542\/peds.109.1.e13","article-title":"Increased prevalence of mutations in the cystic fibrosis transmembrane conductance regulator in children with chronic rhinosinusitis","volume":"109","author":"Raman","year":"2002","journal-title":"Pediatrics"},{"key":"10.1016\/j.cppeds.2024.101637_bib0088","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/humu.20232","article-title":"Increased risk of idiopathic chronic pancreatitis in cystic fibrosis carriers","volume":"26","author":"Cohn","year":"2005","journal-title":"Hum Mutat"},{"key":"10.1016\/j.cppeds.2024.101637_bib0089","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJM199809033391001","article-title":"Mutations of the cystic fibrosis gene in patients with chronic pancreatitis","volume":"339","author":"Sharer","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cppeds.2024.101637_bib0090","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/s004390100467","article-title":"CFTR gene mutations\u2014Including three novel nucleotide substitutions\u2014 and haplotype background in patients with asthma, disseminated bronchiectasis, and chronic obstructive pulmonary disease","volume":"108","author":"Tzetis","year":"2001","journal-title":"Hum Genet"},{"key":"10.1016\/j.cppeds.2024.101637_bib0091","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1159\/000484750","article-title":"CFTR gene mutations in adults with disseminated bronchiectasis","volume":"5","author":"Girodon","year":"1997","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.cppeds.2024.101637_bib0092","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00558-2020","article-title":"Morbidity and mortality in carriers of the cystic fibrosis mutation CFTR Phe508del in the general population","volume":"56","author":"\u00c7olak","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.cppeds.2024.101637_bib0093","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1073\/pnas.1914912117","article-title":"Cystic fibrosis carriers are at increased risk for a wide range of cystic fibrosis-related conditions","volume":"117","author":"Miller","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cppeds.2024.101637_bib0094","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.3390\/jcm9123853","article-title":"Extensive CFTR gene analysis revealed a higher occurrence of cystic fibrosis transmembrane regulator-related disorders (CFTR-RD) among CF carriers","volume":"9","author":"Esposito","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.cppeds.2024.101637_bib0095","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02645-2020","article-title":"Carriers of a single CFTR mutation are asymptomatic: an evolving dogma?","volume":"56","author":"Martin","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.cppeds.2024.101637_bib0096","article-title":"Risk for dehydration and fluid and electrolyte disorders among cystic fibrosis carriers","author":"Lee","year":"2023","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.cppeds.2024.101637_bib0097","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2024.01.012","article-title":"ECFS standards of care on CFTR-related disorders: towards a comprehensive program for affected individuals","author":"De Wachter","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.cppeds.2024.101637_bib0098","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1164\/rccm.201304-0733OC","article-title":"Cigarette smoke induces systemic defects in cystic fibrosis transmembrane conductance regulator function","volume":"188","author":"Raju","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.cppeds.2024.101637_bib0099","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1183\/09031936.00057309","article-title":"Combination of ENaC and CFTR mutations may predispose to cystic fibrosis-like disease","volume":"34","author":"Fajac","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1016\/j.cppeds.2024.101637_bib0100","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1001\/jama.2023.8120","article-title":"Cystic fibrosis: a review","volume":"329","author":"Ong","year":"2023","journal-title":"JAMA"},{"issue":"18","key":"10.1016\/j.cppeds.2024.101637_bib0101","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMra2216474","article-title":"Cystic fibrosis","volume":"389","author":"Grasemann","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cppeds.2024.101637_bib0102","article-title":"Diagnosis of cystic fibrosis: consensus guidelines from the cystic fibrosis foundation","author":"Farrell","year":"2017","journal-title":"J Pediatr"},{"key":"10.1016\/j.cppeds.2024.101637_bib0103","first-page":"181S","article-title":"Diagnosis of cystic fibrosis in screened populations","author":"Farrell","year":"2017","journal-title":"J Pediatr"},{"key":"10.1016\/j.cppeds.2024.101637_bib0104","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2016.09.068","article-title":"Diagnosis of cystic fibrosis in nonscreened populations","author":"Sosnay","year":"2017","journal-title":"J Pediatr"},{"key":"10.1016\/j.cppeds.2024.101637_bib0105","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nrg3849","article-title":"Cystic fibrosis genetics: from molecular understanding to clinical application","volume":"16","author":"Cutting","year":"2015","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.cppeds.2024.101637_bib0106","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jcf.2008.03.009","article-title":"Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice","volume":"7","author":"Castellani","year":"2008","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.cppeds.2024.101637_bib0107","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.3389\/fphar.2019.01662","article-title":"CFTR modulators: the changing face of cystic fibrosis in the era of precision medicine","volume":"10","author":"Lopes-Pacheco","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.cppeds.2024.101637_bib0108","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1136\/jmedgenet-2016-103985","article-title":"Genotype-phenotype correlation and functional studies in patients with cystic fibrosis bearing CFTR complex alleles","volume":"54","author":"Terlizzi","year":"2017","journal-title":"J Med Genet"},{"key":"10.1016\/j.cppeds.2024.101637_bib0109","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.3390\/jpm12091421","article-title":"Modulator therapy in cystic fibrosis patients with cis variants in F508del complex allele: a short-term observational case series","volume":"12","author":"Terlizzi","year":"2022","journal-title":"J Pers Med"},{"key":"10.1016\/j.cppeds.2024.101637_bib0110","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1375\/136905200320565256","article-title":"Categories of delta F508 homozygous cystic fibrosis twin and sibling pairs with distinct phenotypic characteristics","volume":"3","author":"Mekus","year":"2000","journal-title":"Twin Res"},{"key":"10.1016\/j.cppeds.2024.101637_bib0111","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.jpeds.2010.05.018","article-title":"Quantification of the relative contribution of environmental and genetic factors to variation in cystic fibrosis lung function","volume":"157","author":"Collaco","year":"2010","journal-title":"J Pediatr"},{"key":"10.1016\/j.cppeds.2024.101637_bib0112","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s12890-018-0766-6","article-title":"F. Clinical expression of cystic fibrosis in a large cohort of Italian siblings","volume":"18","author":"Terlizzi","year":"2018","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.cppeds.2024.101637_bib0113","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/MCP.0000000000000479","article-title":"Disease-modifying genetic factors in cystic fibrosis","volume":"24","author":"Marson","year":"2018","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.cppeds.2024.101637_bib0114","doi-asserted-by":"crossref","first-page":"5821","DOI":"10.3390\/jcm10245821","article-title":"Genetic modifying factors of cystic fibrosis phenotype: a challenge for modern medicine","volume":"10","author":"Butnariu","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.cppeds.2024.101637_bib0115","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/glycob\/cwq161","article-title":"Impact of mannose-binding lectin insufficiency on the course of cystic fibrosis: a review and meta-analysis","volume":"21","author":"Chalmers","year":"2011","journal-title":"Glycobiology"},{"key":"10.1016\/j.cppeds.2024.101637_bib0116","first-page":"1959","article-title":"The role of CFTR\/ENaC genotype in cystic fibrosis-like phenotypes","volume":"44","author":"Norek","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.cppeds.2024.101637_bib0117","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1001\/jama.2009.1295","article-title":"Gene Modifier Study Group. Genetic modifiers of liver disease in cystic fibrosis","volume":"302","author":"Bartlett","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.cppeds.2024.101637_bib0118","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/ajmg.10461","article-title":"Genotype-phenotype correlation in cystic fibrosis: the role of modifier genes","volume":"111","author":"Salvatore","year":"2002","journal-title":"Am J Med Genet"},{"key":"10.1016\/j.cppeds.2024.101637_bib0119","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s10020-018-0041-6","article-title":"Trans-heterozygosity for mutations enhances the risk of recurrent\/chronic pancreatitis in patients with Cystic Fibrosis","volume":"24","author":"Sofia","year":"2018","journal-title":"Mol Med"},{"key":"10.1016\/j.cppeds.2024.101637_bib0120","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.jcf.2020.02.004","article-title":"Tobacco smoke exposure and socioeconomic factors are independent predictors of pulmonary decline in pediatric cystic fibrosis","volume":"19","author":"Oates","year":"2020","journal-title":"J Cyst Fibros"},{"issue":"Suppl 1","key":"10.1016\/j.cppeds.2024.101637_bib0121","doi-asserted-by":"crossref","first-page":"eS30","DOI":"10.1016\/S0929-693X(20)30048-8","article-title":"Genetic counseling for cystic fibrosis: a basic model with new challenges","volume":"27","author":"Bieth","year":"2020","journal-title":"Arch Pediatr"},{"key":"10.1016\/j.cppeds.2024.101637_bib0122","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jcf.2018.11.014","article-title":"The increasing challenge of genetic counseling for cystic fibrosis","volume":"18","author":"Foil","year":"2019","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.cppeds.2024.101637_bib0123","first-page":"9","article-title":"Hyperechogenic fetal bowel: an ultrasonographic marker for adverse fetal and neonatal outcome?","volume":"5","author":"De Oronzo","year":"2011","journal-title":"J Prenat Med"},{"key":"10.1016\/j.cppeds.2024.101637_bib0124","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jcf.2022.10.002","article-title":"Standards of care for CFTR variant-specific therapy (including modulators) for people with cystic fibrosis","volume":"22","author":"Southern","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.cppeds.2024.101637_bib0125","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/andr.12450","article-title":"Congenital bilateral absence of the vas deferens as an atypical form of cystic fibrosis: reproductive implications and genetic counseling","volume":"6","author":"de Souza","year":"2018","journal-title":"Andrology"},{"issue":"4","key":"10.1016\/j.cppeds.2024.101637_bib0126","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMra1300109","article-title":"Origins of cystic fibrosis lung disease","volume":"372","author":"Stoltz","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cppeds.2024.101637_bib0127","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1136\/thx.2010.139493","article-title":"Evolution of pulmonary inflammation and nutritional status in infants and young children with cystic fibrosis","volume":"66","author":"Ranganathan","year":"2011","journal-title":"Thorax"},{"key":"10.1016\/j.cppeds.2024.101637_bib0128","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/cid\/cir399","article-title":"Inflammatory responses to individual microorganisms in the lungs of children with cystic fibrosis","volume":"53","author":"Gangell","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.cppeds.2024.101637_bib0129","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.3390\/cells12081104","article-title":"Inflammation as a regulator of the airway surface liquid pH in cystic fibrosis","volume":"12","author":"Rehman","year":"2023","journal-title":"Cells"},{"issue":"6","key":"10.1016\/j.cppeds.2024.101637_bib0130","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/MCP.0b013e32834b14c9","article-title":"New animal models of cystic fibrosis: what are they teaching us?","volume":"17","author":"Keiser","year":"2011","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.cppeds.2024.101637_bib0131","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1056\/NEJMoa1301725","article-title":"Risk factors for bronchiectasis in children with cystic fibrosis","volume":"368","author":"Sly","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cppeds.2024.101637_bib0132","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1164\/rccm.200901-0069OC","article-title":"Lung disease at diagnosis in infants with cystic fibrosis detected by newborn screening","volume":"180","author":"Sly","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.cppeds.2024.101637_bib0133","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.jcf.2018.01.006","article-title":"Wisconsin CF Neonatal Screening Group. Early life growth patterns persist for 12 years and impact pulmonary outcomes in cystic fibrosis","volume":"17","author":"Sanders","year":"2018","journal-title":"J Cyst Fibros"},{"issue":"6 Suppl","key":"10.1016\/j.cppeds.2024.101637_bib0134","first-page":"S73","article-title":"Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis","volume":"155","author":"Cystic Fibrosis Foundation","year":"2009","journal-title":"J Pediatr"},{"issue":"4","key":"10.1016\/j.cppeds.2024.101637_bib0135","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/ppul.25825","article-title":"Vitamins A, D, E status as related to supplementation and lung disease markers in young children with cystic fibrosis","volume":"57","author":"Lai","year":"2022","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.cppeds.2024.101637_bib0136","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.clnesp.2022.07.018","article-title":"Genetic factors help explain the variable responses of young children with cystic fibrosis to vitamin D supplements","volume":"51","author":"Lai","year":"2022","journal-title":"Clin Nutr ESPEN"},{"issue":"5","key":"10.1016\/j.cppeds.2024.101637_bib0137","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.3945\/ajcn.110.004119","article-title":"Growth and pulmonary outcomes during the first 2 y of life of breastfed and formula-fed infants diagnosed with cystic fibrosis through the Wisconsin Routine Newborn Screening Program","volume":"93","author":"Jadin","year":"2011","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.cppeds.2024.101637_bib0138","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1164\/rccm.201606-1107CI","article-title":"Early lung disease in infants and preschool children with cystic fibrosis. What have we learned and what should we do about it?","volume":"195","author":"Ranganathan","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.cppeds.2024.101637_bib0139","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.jpeds.2009.05.005","article-title":"Bronchiectasis in infants and preschool children diagnosed with cystic fibrosis after newborn screening","volume":"155","author":"Stick","year":"2009","journal-title":"J Pediatr"},{"key":"10.1016\/j.cppeds.2024.101637_bib0140","doi-asserted-by":"crossref","first-page":"25898","DOI":"10.3402\/ecrj.v1.25898","article-title":"Techniques of assessing small airways dysfunction","volume":"1","author":"McNulty","year":"2014","journal-title":"Eur Clin Respir J"},{"key":"10.1016\/j.cppeds.2024.101637_bib0141","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1136\/thoraxjnl-2020-216085","article-title":"Time to get serious about the detection and monitoring of early lung disease in cystic fibrosis","volume":"76","author":"Bayfield","year":"2021","journal-title":"Thorax"},{"key":"10.1016\/j.cppeds.2024.101637_bib0142","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2024.01.005","article-title":"Standards for the care of people with cystic fibrosis (CF); recognizing and addressing CF health issues","author":"Burgel","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.cppeds.2024.101637_bib0143","doi-asserted-by":"crossref","first-page":"557","DOI":"10.2214\/ajr.163.3.8079843","article-title":"Radiographic changes in acute exacerbations of cystic fibrosis in adults: a pilot study","volume":"163","author":"Greene","year":"1994","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.cppeds.2024.101637_bib0144","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1136\/thx.2007.082628","article-title":"Lung clearance index is a sensitive, repeatable and practical measure of airways disease in adults with cystic fibrosis","volume":"63","author":"Horsley","year":"2008","journal-title":"Thorax"},{"key":"10.1016\/j.cppeds.2024.101637_bib0145","first-page":"1625","article-title":"Effect of dornase alfa on the lung clearance index in children with cystic fibrosis: a lesson from a case series","volume":"9","author":"Terlizzi","year":"2022","journal-title":"Children (Basel)"},{"key":"10.1016\/j.cppeds.2024.101637_bib0146","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1136\/thx.2010.150375","article-title":"Lung clearance index and HRCT are complementary markers of lung abnormalities in young children with CF","volume":"66","author":"Owens","year":"2011","journal-title":"Thorax"},{"key":"10.1016\/j.cppeds.2024.101637_bib0147","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1136\/thx.2004.022590","article-title":"Multiple breath inert gas washout as a measure of ventilation distribution in children with cystic fibrosis","volume":"59","author":"Aurora","year":"2004","journal-title":"Thorax"},{"key":"10.1016\/j.cppeds.2024.101637_bib0148","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1164\/rccm.201507-1409OC","article-title":"Lung clearance index and structural lung disease on computed tomography in early cystic fibrosis","volume":"193","author":"Ramsey","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.cppeds.2024.101637_bib0149","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1164\/rccm.202202-0392OC","article-title":"efficacy and safety of Elexacaftor\/Tezacaftor\/Ivacaftor in children 6 through 11 years of age with cystic fibrosis heterozygous for f508del and a minimal function mutation: a phase 3b, randomized, placebo-controlled study","volume":"206","author":"Mall","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.cppeds.2024.101637_bib0150","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s00247-022-05522-4","article-title":"Chest radiography and computed tomography imaging in cystic fibrosis: current challenges and new perspectives","volume":"53","author":"Ciet","year":"2023","journal-title":"Pediatr Radiol"},{"key":"10.1016\/j.cppeds.2024.101637_bib0151","first-page":"522","article-title":"Cystic fibrosis pulmonary guidelines: airway clearance therapies","volume":"54","author":"Flume","year":"2009","journal-title":"Respir Care"},{"issue":"1","key":"10.1016\/j.cppeds.2024.101637_bib0152","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00286-2023","article-title":"Implementation and evaluation of ultra-low dose CT in early cystic fibrosis lung disease","volume":"62","author":"Bayfield","year":"2023","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.cppeds.2024.101637_bib0153","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1007\/s00247-020-04706-0","article-title":"Computed tomography in cystic fibrosis lung disease: a focus on radiation exposure","volume":"51","author":"Joyce","year":"2021","journal-title":"Pediatr Radiol"},{"issue":"2","key":"10.1016\/j.cppeds.2024.101637_bib0154","doi-asserted-by":"crossref","first-page":"e148","DOI":"10.1016\/j.jcf.2021.11.006","article-title":"Magnetic resonance imaging of cystic fibrosis: multi-organ imaging in the age of CFTR modulator therapies","volume":"21","author":"McBennett","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"8","key":"10.1016\/j.cppeds.2024.101637_bib0155","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1164\/rccm.202102-0278OC","article-title":"Magnetic resonance imaging detects progression of lung disease and impact of newborn screening in preschool children with cystic fibrosis","volume":"204","author":"Stahl","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.cppeds.2024.101637_bib0156","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1164\/rccm.202201-0219OC","article-title":"Effects of Elexacaftor\/Tezacaftor\/Ivacaftor therapy on lung clearance index and magnetic resonance imaging in patients with cystic fibrosis and one or two F508del alleles","volume":"206","author":"Graeber","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.cppeds.2024.101637_bib0157","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2024.01.004","article-title":"Elexacaftor\/tezacaftor\/ivacaftor improves chronic rhinosinusitis detected by magnetic resonance imaging in children with cystic fibrosis on long-term therapy with lumacaftor\/ivacaftor","author":"Wucherpfennig","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"15","key":"10.1016\/j.cppeds.2024.101637_bib0158","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.3390\/jcm11154277","article-title":"Early effects of elexacaftor-tezacaftor-ivacaftor therapy on magnetic resonance imaging in patients with cystic fibrosis and advanced lung disease","volume":"11","author":"Macconi","year":"2022","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.cppeds.2024.101637_bib0159","article-title":"Conventional chest physiotherapy compared to other airway clearance techniques for cystic fibrosis","author":"Main","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1016\/j.cppeds.2024.101637_bib0160","article-title":"Conventional chest physiotherapy compared to other airway clearance techniques for cystic fibrosis","volume":"5","author":"Main","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.cppeds.2024.101637_bib0161","article-title":"Active cycle of breathing technique for cystic fibrosis","volume":"2","author":"Wilson","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cppeds.2024.101637_bib0162","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1164\/rccm.201207-1160OE","article-title":"Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health","volume":"187","author":"Mogayzel","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.cppeds.2024.101637_bib0163","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001401","article-title":"Chest physiotherapy compared to no chest physiotherapy for cystic fibrosis","author":"van der Schans","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"10.1016\/j.cppeds.2024.101637_bib0164","first-page":"1276","article-title":"The evidence for secretion clearance techniques","volume":"46","author":"Hess","year":"2001","journal-title":"Respir Care"},{"key":"10.1016\/j.cppeds.2024.101637_bib0165","article-title":"Dornase alfa for cystic fibrosis","volume":"3","author":"Yang","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cppeds.2024.101637_bib0166","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13052-022-01331-5","article-title":"Dornase alfa in cystic fibrosis: indications, comparative studies and effects on lung clearance index","volume":"48","author":"Terlizzi","year":"2022","journal-title":"Ital J Pediatr"},{"key":"10.1016\/j.cppeds.2024.101637_bib0167","article-title":"S. Standards for the care of people with cystic fibrosis; establishing and maintaining health","author":"Southern","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.cppeds.2024.101637_bib0168","article-title":"Timing of dornase alfa inhalation for cystic fibrosis","volume":"3","author":"Dentice","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cppeds.2024.101637_bib0169","article-title":"Nebulised hypertonic saline for cystic fibrosis","volume":"6","author":"Wark","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cppeds.2024.101637_bib0170","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s13052-021-01117-1","article-title":"Hypertonic saline in people with cystic fibrosis: review of comparative studies and clinical practice","volume":"47","author":"Terlizzi","year":"2021","journal-title":"Ital J Pediatr"},{"key":"10.1016\/j.cppeds.2024.101637_bib0171","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa043900","article-title":"A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis","volume":"354","author":"Elkins","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cppeds.2024.101637_bib0172","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S2213-2600(21)00546-4","article-title":"The effect of inhaled hypertonic saline on lung structure in children aged 3-6 years with cystic fibrosis (SHIP-CT): a multicentre, randomised, double-blind, controlled trial","volume":"10","author":"Tiddens","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.cppeds.2024.101637_bib0173","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1164\/rccm.201807-1203OC","article-title":"Preventive Inhalation of Hypertonic Saline in Infants with Cystic Fibrosis (PRESIS). A randomized, double-blind, controlled study","volume":"199","author":"Stahl","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.cppeds.2024.101637_bib0174","article-title":"Nebulised hypertonic saline for cystic fibrosis","volume":"6","author":"Wark","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cppeds.2024.101637_bib0175","article-title":"Inhaled mannitol for cystic fibrosis","volume":"5","author":"Nevitt","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cppeds.2024.101637_bib0176","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1164\/rccm.200812-1845PP","article-title":"Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations","volume":"180","author":"Flume","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.cppeds.2024.101637_bib0177","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jcf.2004.03.008","article-title":"Consensus Study Group. Early intervention and prevention of lung disease in cystic fibrosis: a European consensus","volume":"3","author":"D\u00f6ring","year":"2004","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.cppeds.2024.101637_bib0178","article-title":"Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis","volume":"6","author":"Langton Hewer","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.cppeds.2024.101637_bib0179","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1569-1993(02)00141-8","article-title":"Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients","volume":"2","author":"Lee","year":"2003","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.cppeds.2024.101637_bib0180","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1183\/09031936.06.00100805","article-title":"Evaluating the \"Leeds criteria\" for Pseudomonas aeruginosa infection in a cystic fibrosis centre","volume":"27","author":"Proesmans","year":"2006","journal-title":"Eur Respir J"},{"key":"10.1016\/j.cppeds.2024.101637_bib0181","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jcf.2009.08.004","article-title":"Aminoglycoside therapy against Pseudomonas aeruginosa in cystic fibrosis: a review","volume":"8","author":"Ratjen","year":"2009","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.cppeds.2024.101637_bib0182","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jcf.2004.10.003","article-title":"Immunisation in the current management of cystic fibrosis patients","volume":"4","author":"Malfroot","year":"2005","journal-title":"J Cyst Fibros"},{"issue":"5","key":"10.1016\/j.cppeds.2024.101637_bib0183","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/j.1651-2227.1981.tb05757.x","article-title":"Respiratory infections in cystic fibrosis patients caused by virus, chlamydia and mycoplasma\u2013possible synergism with Pseudomonas aeruginosa","volume":"70","author":"Petersen","year":"1981","journal-title":"Acta Paediatr Scand"},{"key":"10.1016\/j.cppeds.2024.101637_bib0184","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.3389\/fimmu.2018.03067","article-title":"Viral-bacterial co-infections in the cystic fibrosis respiratory tract","volume":"9","author":"Kiedrowski","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.cppeds.2024.101637_bib0185","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/00004630-200109000-00004","article-title":"Pseudomonas vaccination and immunotherapy: an overview","volume":"5","author":"Holder","year":"2001","journal-title":"J Burn Care Rehabil"},{"issue":"9","key":"10.1016\/j.cppeds.2024.101637_bib0186","article-title":"Pneumococcal vaccines for cystic fibrosis","volume":"9","author":"Burgess","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cppeds.2024.101637_bib0187","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2022.958658","article-title":"Risk factors for severe COVID-19 in people with cystic fibrosis: a systematic review","volume":"10","author":"Terlizzi","year":"2022","journal-title":"Front Pediatr"},{"key":"10.1016\/j.cppeds.2024.101637_bib0188","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.jcf.2021.03.028","article-title":"COVID-19 vaccine prioritisation for people with cystic fibrosis","volume":"20","author":"Carr","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.cppeds.2024.101637_bib0189","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jcf.2007.05.002","article-title":"Is there a role for influenza vaccination in cystic fibrosis?","volume":"7","author":"Wat","year":"2008","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.cppeds.2024.101637_bib0190","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1086\/313823","article-title":"Immunisation of pediatric solid organ transplant candidates and recipients","volume":"30","author":"Burroughs","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cppeds.2024.101637_bib0191","doi-asserted-by":"crossref","first-page":"18825","DOI":"10.1073\/pnas.0904709106","article-title":"Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770","volume":"106","author":"Van Goor","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cppeds.2024.101637_bib0192","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cppeds.2024.101637_bib0193","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2020.106073","article-title":"Ivacaftor improves lung disease in patients with advanced CF carrying CFTR mutations that confer residual function","volume":"171","author":"Salvatore","year":"2020","journal-title":"Respir Med"},{"key":"10.1016\/j.cppeds.2024.101637_bib0194","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S2213-2600(15)00201-5","article-title":"Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial","volume":"3","author":"Moss","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.cppeds.2024.101637_bib0195","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/ppul.23659","article-title":"In vivo and in vitro ivacaftor response in cystic fibrosis patients with residual CFTR function: N-of-1 studies","volume":"52","author":"McGarry","year":"2017","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.cppeds.2024.101637_bib0196","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1164\/rccm.202008-3177OC","article-title":"Ivacaftor in infants aged 4 to <12 months with cystic fibrosis and a gating mutation. Results of a two-part phase 3 clinical trial","volume":"203","author":"Davies","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.cppeds.2024.101637_bib0197","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.jcf.2014.04.003","article-title":"Combined effects of VX-770 and VX-809 on several functional abnormalities of F508del-CFTR channels","volume":"13","author":"Kopeikin","year":"2014","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.cppeds.2024.101637_bib0198","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cppeds.2024.101637_bib0199","first-page":"75","article-title":"Clinical effectiveness of lumacaftor\/ivacaftor in patients with cystic fibrosis homozygous for F508del-CFTR. A clinical trial","volume":"18","author":"Sagel","year":"2021"},{"key":"10.1016\/j.cppeds.2024.101637_bib0200","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1164\/rccm.202204-0734OC","article-title":"A phase 3, open-label study of lumacaftor\/ivacaftor in children 1 to less than 2 years of age with cystic fibrosis homozygous for F508del-CFTR","volume":"206","author":"Rayment","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"21","key":"10.1016\/j.cppeds.2024.101637_bib0201","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1056\/NEJMoa1709846","article-title":"Tezacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del","volume":"377","author":"Taylor-Cousar","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cppeds.2024.101637_bib0202","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1056\/NEJMoa1709847","article-title":"Tezacaftor-ivacaftor in residual-function heterozygotes with cystic fibrosis","volume":"377","author":"Rowe","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cppeds.2024.101637_bib0203","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1056\/NEJMoa1807120","article-title":"VX-445-tezacaftor-ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles","volume":"379","author":"Keating","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cppeds.2024.101637_bib0204","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jcf.2020.07.023","volume":"20","author":"Davies","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.cppeds.2024.101637_bib0205","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.jcf.2022.12.006","article-title":"Long-term tezacaftor\/ivacaftor safety and efficacy in people with cystic fibrosis and an F508del-CFTR mutation: 96-week, open-label extension of the EXTEND trial","volume":"22","author":"Flume","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.cppeds.2024.101637_bib0206","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.cppeds.2024.101637_bib0207","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single F508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cppeds.2024.101637_bib0208","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.03079-2020","article-title":"Efficacy of elexacaftor\/tezacaftor\/ivacaftor in patients with cystic fibrosis and advanced lung disease","volume":"57","author":"O'Shea","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.cppeds.2024.101637_bib0209","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1164\/rccm.202011-4153OC","article-title":"Rapid improvement after starting elexacaftor-tezacaftor-ivacaftor in patients with cystic fibrosis and advanced pulmonary disease","volume":"204","author":"Burgel","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"10.1016\/j.cppeds.2024.101637_bib0210","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.3390\/genes12081178","article-title":"Effectiveness of elexacaftor\/tezacaftor\/ivacaftor therapy in three subjects with the cystic fibrosis genotype Phe508del\/unknown and advanced lung disease","volume":"12","author":"Terlizzi","year":"2021","journal-title":"Genes (Basel)"},{"issue":"7","key":"10.1016\/j.cppeds.2024.101637_bib0211","doi-asserted-by":"crossref","first-page":"828","DOI":"10.3390\/antibiotics10070828","article-title":"Elexacaftor-tezacaftor-ivacaftor therapy for cystic fibrosis patients with the F508del\/unknown genotype","volume":"10","author":"Comegna","year":"2021","journal-title":"Antibiotics"},{"key":"10.1016\/j.cppeds.2024.101637_bib0212","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1056\/NEJMoa2100665","article-title":"Triple therapy for cystic fibrosis Phe508del-gating and -residual function genotypes","volume":"385","author":"Barry","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cppeds.2024.101637_bib0213","article-title":"Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del)","volume":"11","author":"Heneghan","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cppeds.2024.101637_bib0214","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1164\/rccm.202301-0021OC","article-title":"Long-term safety and efficacy of elexacaftor\/tezacaftor\/ivacaftor in children aged \u2a7e6 years with cystic fibrosis and at least one F508del allele: a phase 3, open-label clinical trial","volume":"208","author":"Wainwright","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.cppeds.2024.101637_bib0215","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1164\/rccm.202301-0084OC","article-title":"Phase 3 open-label clinical trial of elexacaftor\/tezacaftor\/ivacaftor in children aged 2-5 years with cystic fibrosis and at least one F508del allele","volume":"208","author":"Goralski","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"issue":"4 Suppl 2","key":"10.1016\/j.cppeds.2024.101637_bib0216","first-page":"1","article-title":"Registro italiano Fibrosi Cistica (RIFC). Rapporto 2019-2020 [Italian Cystic Fibrosis Registry (ICFR). Report 2019-2020]","volume":"46","author":"Campagna","year":"2022","journal-title":"Epidemiol Prev"},{"key":"10.1016\/j.cppeds.2024.101637_bib0217","article-title":"Global disparities in cystic fibrosis outcomes prior to CFTR modulators: a CF registries cohort study in South Africa and Canada","author":"Zampoli","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.cppeds.2024.101637_bib0218","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.14309\/ajg.0000000000001527","article-title":"Cystic fibrosis transmembrane conductance regulator modulator use is associated with reduced pancreatitis hospitalizations in patients with cystic fibrosis","volume":"116","author":"Ramsey","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cppeds.2024.101637_bib0219","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S2213-2600(23)00324-7","article-title":"Understanding and addressing the needs of people with cystic fibrosis in the era of CFTR modulator therapy","volume":"11","author":"Hisert","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.cppeds.2024.101637_bib0220","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jcf.2023.02.004","article-title":"Elexacaftor\/tezacaftor\/ivacaftor projected survival and long-term health outcomes in people with cystic fibrosis homozygous for F508del","volume":"22","author":"Lopez","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.cppeds.2024.101637_bib0221","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1164\/rccm.202308-1317OC","article-title":"Improvement in lung clearance index and chest computed tomography scores with elexacaftor\/tezacaftor\/ivacaftor treatment in people with cystic fibrosis aged 12 years and older - the RECOVER trial","volume":"208","author":"McNally","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.cppeds.2024.101637_bib0222","first-page":"252","article-title":"Nutritional status and circulating levels of fat-soluble vitamins in cystic fibrosis patients: a cohort study and evaluation of the effect of CFTR modulators","volume":"10","author":"Francalanci","year":"2023","journal-title":"Children (Basel)"},{"key":"10.1016\/j.cppeds.2024.101637_bib0223","doi-asserted-by":"crossref","first-page":"449","DOI":"10.3390\/genes14020449","article-title":"Effects of Elexacaftor\/Tezacaftor\/Ivacaftor on cardiorespiratory polygraphy parameters and respiratory muscle strength in cystic fibrosis patients with severe lung disease","volume":"14","author":"Giallongo","year":"2023","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.cppeds.2024.101637_bib0224","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jcf.2021.09.001","article-title":"The effect of elexacaftor\/tezacaftor\/ivacaftor (ETI) on glycemia in adults with cystic fibrosis","volume":"21","author":"Scully","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.cppeds.2024.101637_bib0225","article-title":"Effect of elexacaftor\/tezacaftor\/ivacaftor on mucus and mucociliary clearance in cystic fibrosis","author":"Donaldson","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.cppeds.2024.101637_bib0226","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jcf.2021.02.003","article-title":"PROMISE: working with the CF community to understand emerging clinical and research needs for those treated with highly effective CFTR modulator therapy","volume":"20","author":"Nichols","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.cppeds.2024.101637_bib0227","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2023.10.001","article-title":"Reduction in abdominal symptoms (CFAbd-Score), faecal M2-pyruvate-kinase and Calprotectin over one year of treatment with Elexacaftor-Tezacaftor-Ivacaftor in people with CF aged \u226512 years - The RECOVER study","author":"Mainz","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.cppeds.2024.101637_bib0228","doi-asserted-by":"crossref","DOI":"10.1172\/JCI167957","article-title":"Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist","volume":"133","author":"Nichols","year":"2023","journal-title":"J Clin Invest"},{"key":"10.1016\/j.cppeds.2024.101637_bib0229","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1016\/S2213-2600(23)00223-0","article-title":"Reducing treatment burden in the era of CFTR modulators","volume":"11","author":"Robinson","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.cppeds.2024.101637_bib0230","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S2213-2600(22)00434-9","article-title":"Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials","volume":"11","author":"Mayer-Hamblett","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.cppeds.2024.101637_bib0231","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2023.01.007","article-title":"Effects of elexacaftor\/tezacaftor\/ivacaftor on liver fibrosis markers in adults with cystic fibrosis","author":"Tewkesbury","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.cppeds.2024.101637_bib0232","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02029-2022","article-title":"Long-term safety and efficacy of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis and at least one F508del allele: 144-week interim results from a 192-week open-label extension study","volume":"62","author":"Daines","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.cppeds.2024.101637_bib0233","article-title":"Elexacaftor\/Tezacaftor\/Ivacaftor treatment and depression-related events","author":"Ramsey","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.cppeds.2024.101637_bib0234","doi-asserted-by":"crossref","first-page":"3626","DOI":"10.1002\/ppul.26673","article-title":"Prevalence of adverse events in cystic fibrosis patients treated with Elexacaftor\/Tezacaftor\/Ivacaftor: experience of the regional referral center in Tuscany, Italy","volume":"58","author":"Manciulli","year":"2023","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.cppeds.2024.101637_bib0235","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1164\/rccm.202303-0380LE","article-title":"Raised intracranial pressure in three children with cystic fibrosis receiving elexacaftor-tezacaftor-ivacaftor modulator therapy","volume":"208","author":"Southern","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.cppeds.2024.101637_bib0236","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ccm.2022.06.009","article-title":"Update on clinical outcomes of highly effective modulator therapy","volume":"43","author":"Gifford","year":"2022","journal-title":"Clin Chest Med"},{"key":"10.1016\/j.cppeds.2024.101637_bib0237","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S2213-2600(22)00504-5","article-title":"Safety and efficacy of vanzacaftor-tezacaftor-deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials","volume":"11","author":"Uluer","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.cppeds.2024.101637_bib0238","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/S2213-2600(23)00297-7","article-title":"Advancing the pipeline of cystic fibrosis clinical trials: a new roadmap with a global trial network perspective","volume":"11","author":"Mayer-Hamblett","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.cppeds.2024.101637_bib0239","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s41467-023-36244-2","article-title":"Future therapies for cystic fibrosis","volume":"14","author":"Allen","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.cppeds.2024.101637_bib0240","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.3390\/cells12121555","article-title":"Genome editing for cystic fibrosis","volume":"12","author":"Wang","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.cppeds.2024.101637_bib0241","doi-asserted-by":"crossref","first-page":"536","DOI":"10.3390\/cells12040536","article-title":"Prime editing for human gene therapy: where are we now?","volume":"12","author":"Godbout","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.cppeds.2024.101637_bib0242","first-page":"2281","article-title":"Genome engineering using the CRISPR-Cas9 system","volume":"8","author":"Ran","year":"2013","journal-title":"NatProtoc"},{"key":"10.1016\/j.cppeds.2024.101637_bib0243","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.stem.2013.11.002","article-title":"Functional repair of CFTR by CRISPR\/Cas9 in intestinal stem cell organoids of cystic fibrosis patients","volume":"13","author":"Schwank","year":"2013","journal-title":"Cell Stem Cell"},{"issue":"7","key":"10.1016\/j.cppeds.2024.101637_bib0244","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/nm.3201","article-title":"A functional CFTR assay using primary cystic fibrosis intestinal organoids","volume":"19","author":"Dekkers","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.cppeds.2024.101637_bib0245","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.celrep.2015.07.062","article-title":"Functional gene correction for cystic fibrosis in lung epithelial cells generated from patient iPSCs","volume":"12","author":"Firth","year":"2015","journal-title":"Cell Rep"},{"key":"10.1016\/j.cppeds.2024.101637_bib0246","doi-asserted-by":"crossref","DOI":"10.3389\/fgeed.2022.917916","article-title":"Editorial: genome editing to treat cystic fibrosis and other pulmonary diseases","volume":"4","author":"Vaidyanathan","year":"2022","journal-title":"Front Genome Ed"},{"key":"10.1016\/j.cppeds.2024.101637_bib0247","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1089\/hum.2015.069","article-title":"Challenges in CRISPR\/CAS9 delivery: potential roles of nonviral vectors","volume":"26","author":"Li","year":"2015","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.cppeds.2024.101637_bib0248","doi-asserted-by":"crossref","DOI":"10.3389\/fgeed.2020.613252","article-title":"Gene editing and genotoxicity: targeting the off-targets","volume":"2","author":"Blattner","year":"2020","journal-title":"Front Genome Ed"},{"key":"10.1016\/j.cppeds.2024.101637_bib0249","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S2213-2600(15)00245-3","article-title":"Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial","volume":"3","author":"Alton","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.cppeds.2024.101637_bib0250","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0184009","article-title":"Cas9\/gRNA targeted excision of cystic fibrosis-causing deep-intronic splicing mutations restores normal splicing of CFTR mRNA","volume":"12","author":"Sanz","year":"2017","journal-title":"PLoS ONE"},{"issue":"11","key":"10.1016\/j.cppeds.2024.101637_bib0251","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0295009","article-title":"Prime editing-mediated correction of the CFTR W1282X mutation in iPSCs and derived airway epithelial cells","volume":"18","author":"Li","year":"2023","journal-title":"PLoS ONE"},{"key":"10.1016\/j.cppeds.2024.101637_bib0252","doi-asserted-by":"crossref","DOI":"10.1177\/21501319231173811","article-title":"Integrating primary care into the management of cystic fibrosis","volume":"14","author":"Auth","year":"2023","journal-title":"J Prim Care Community Health"},{"issue":"6","key":"10.1016\/j.cppeds.2024.101637_bib0253","doi-asserted-by":"crossref","first-page":"439","DOI":"10.46747\/cfp.6706439","article-title":"Primary care providers\u2019 role in newborn screening result notification for cystic fibrosis","volume":"67","author":"Hayeems","year":"2021","journal-title":"Can Fam Physician"},{"issue":"6","key":"10.1016\/j.cppeds.2024.101637_bib0254","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.acap.2017.04.010","article-title":"The medical home at 50: are children with medical complexity the key to proving its value?","volume":"17","author":"Lerner","year":"2017","journal-title":"Acad Pediatr"},{"issue":"1","key":"10.1016\/j.cppeds.2024.101637_bib0255","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1186\/s12909-021-02775-9","article-title":"Healthcare workforce transformation: implementing patient-centered medical home standards in an academic medical center","volume":"21","author":"Gendelman","year":"2021","journal-title":"BMC Med Educ"},{"issue":"1","key":"10.1016\/j.cppeds.2024.101637_bib0256","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2019-3451","article-title":"Principles of financing the medical home for children","volume":"145","author":"Price","year":"2020","journal-title":"Pediatrics"},{"issue":"2","key":"10.1016\/j.cppeds.2024.101637_bib0257","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1089\/pop.2017.0066","article-title":"The medical home model and pediatric asthma symptom severity: evidence from a National Health Survey","volume":"21","author":"Rojanasarot","year":"2018","journal-title":"Popul Health Manag"},{"key":"10.1016\/j.cppeds.2024.101637_bib0258","first-page":"181","article-title":"Access to primary care and subspecialty care after positive cystic fibrosis newborn screening","author":"Parker-McGill","year":"2017","journal-title":"Wis Med J"}],"container-title":["Current Problems in Pediatric and Adolescent Health Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538544224000889?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538544224000889?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T22:25:08Z","timestamp":1718490308000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538544224000889"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":258,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S1538544224000889"],"URL":"https:\/\/doi.org\/10.1016\/j.cppeds.2024.101637","relation":{},"ISSN":["1538-5442"],"issn-type":[{"value":"1538-5442","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Update on advances in cystic fibrosis towards a cure and implications for primary care clinicians","name":"articletitle","label":"Article Title"},{"value":"Current Problems in Pediatric and Adolescent Health Care","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cppeds.2024.101637","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101637"}}